

## Common Drug Review \*

### Submission Status



<b>Product:</b>	Actemra		
<b>Generic Name:</b>	tocilizumab		
<b>Manufacturer:</b>	Hoffmann-La Roche Canada		
<b>Indication:</b>	Arthritis, Rheumatoid		
<b>Submission Type:</b>	Initial		
<b>Date Submission Received:</b>	2010-May-27	<b>Date NOC Issued:</b>	2010-Apr-30
<b>Targeted CEDAC Meeting:</b>	2010-Oct-20	<b>Priority Review Granted:</b>	Not Requested

Phase	Target Time (Business Days)	Target Date**	Actual CDR Date	Comments
1	5	2010-Jun-03	2010-Jun-03	Submission deemed complete.
2		2010-Jun-17	2010-Jun-17	Patient group submissions received.
3	45	2010-Aug-19	2010-Sep-02	Reviewer's Reports Sent on 2010-Sep-02
4	7	2010-Aug-30	2010-Sep-14	Manufacturer's Comments expected on 2010-Sep-14 Manufacturer's Comments received on 2010-Sep-14
5		2010-Oct-20	2010-Oct-20	
6	5	2010-Oct-27	2010-Oct-27	
7	10	2010-Nov-10	2010-Nov-10	Embargo Period*** Manufacturers may make a Request for Reconsideration and Drug Plans may make a Request for Clarification of the Recommendation
8 (a)	5	2010-Nov-17	2010-Nov-17	Final Recommendation sent to Drug Plans, ACP, and Manufacturer (No Requests for Clarification are made AND no Request for Reconsideration is made or Request for Reconsideration is Resolved)
OR				
8 (b)	5			Clarification and Final Recommendation sent to Drug Plans, ACP, and Manufacturer (Clarification Requested, no Request for Reconsideration made)
OR				
8 (c)	25 Depends on Meeting Dates			Placed on CEDAC Agenda For Reconsideration (At Manufacturer's request)
9	5			Final Recommendation sent to Drug Plans, ACP, and Manufacturer

\* Refer to the Procedure for Common Drug Review on the Common Drug Review section of [www.cadth.ca](http://www.cadth.ca) for more details.

\*\* The Formulary review process is initiated AFTER a submission is deemed complete. The target dates for this report are based on the CEDAC meeting schedule, which is posted on [www.cadth.ca](http://www.cadth.ca).

\*\*\* The Recommendation is held in confidence and not acted upon until after CADTH has issued the notice of Final Recommendation.

Reflects updates as of Thursday noon.